## Adele Civino

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2594097/publications.pdf

Version: 2024-02-01

623188 500791 38 854 14 28 citations h-index g-index papers 41 41 41 1159 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort. Rheumatology, 2022, 61, 1621-1629.	0.9	5
2	Complications of severe acute respiratory syndrome coronavirus 2 infection in children. Current Opinion in Rheumatology, 2022, 34, 267-273.	2.0	2
3	Comparison Between Clinical and Ultrasound Assessment of the Ankle Region in Children With Juvenile Idiopathic Arthritis. Arthritis Care and Research, 2021, 73, 1180-1186.	1.5	13
4	Development and Testing of Reduced Versions of the Manual Muscle Test-8 in Juvenile Dermatomyositis. Journal of Rheumatology, 2021, 48, 898-906.	1.0	4
5	Defining Kawasaki disease and pediatric inflammatory multisystem syndrome-temporally associated to SARS-CoV-2 infection during SARS-CoV-2 epidemic in Italy: results from a national, multicenter survey. Pediatric Rheumatology, 2021, 19, 29.	0.9	78
6	Multisystem Inflammatory Syndrome in Children: Unique Disease or Part of the Kawasaki Disease Spectrum?. Frontiers in Pediatrics, 2021, 9, 680813.	0.9	24
7	Musculoskeletal manifestations of childhood cancer and differential diagnosis with juvenile idiopathic arthritis (ONCOREUM): a multicentre, cross-sectional study. Lancet Rheumatology, The, 2021, 3, e507-e516.	2.2	12
8	Intra-articular venous malformations of the knee: a diagnostic challenge. Pediatric Rheumatology, 2021, 19, 153.	0.9	2
9	IFNAR2 Deficiency Causing Dysregulation of NK Cell Functions and Presenting With Hemophagocytic Lymphohistiocytosis. Frontiers in Genetics, 2020, 11, 937.	1.1	25
10	The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network;) Tj ETQq0 0 0 rgB	BT/Overlo 2.0	ck 10 Tf 50 3
11	Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis. Rheumatology, 2020, 59, 3505-3514.	0.9	39
12	Comparison of Hodgkin's Lymphoma in Children and Adolescents. A Twenty Year Experience with MH'96 and LH2004 AIEOP (Italian Association of Pediatric Hematology and Oncology) Protocols. Cancers, 2020, 12, 1620.	1.7	10
13	Opportunistic infections in immunosuppressed patients with juvenile idiopathic arthritis: analysis by the Pharmachild Safety Adjudication Committee. Arthritis Research and Therapy, 2020, 22, 71.	1.6	25
14	Disease activity and damage in juvenile idiopathic arthritis: methotrexate era versus biologic era. Arthritis Research and Therapy, 2019, 21, 168.	1.6	37
15	Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis. Rheumatology, 2019, 58, 1196-1205.	0.9	10
16	Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study. The Lancet Child and Adolescent Health, 2019, 3, 255-263.	2.7	120
17	FRIO571â€MEASUREMENT PERFORMANCE OF REDUCED VERSIONS OF MUSCLE STRENGTH TOOLS IN JUVENILI DERMATOMYOSITIS., 2019, , .	E	0
18	THU0655â€LONG-TERM OUTCOME OF JUVENILE IDIOPATHIC ARTHRITIS: COMPARISON OF BIOLOGIC AND METHOTREXATE ERAS. , 2019, , .		0

#	Article	IF	Citations
19	The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 251-258.	1.5	2
20	Development and Testing of a Hybrid Measure of Muscle Strength in Juvenile Dermatomyositis for Use in Routine Care. Arthritis Care and Research, 2018, 70, 1312-1319.	1.5	19
21	Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial. Lancet, The, 2017, 389, 909-916.	6.3	52
22	A national cohort study on pediatric Behçet's disease: cross-sectional data from an Italian registry. Pediatric Rheumatology, 2017, 15, 84.	0.9	55
23	Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept. Pediatric Rheumatology, 2016, 14, 68.	0.9	35
24	The prognostic value of biological markers in paediatric Hodgkin lymphoma. European Journal of Cancer, 2016, 52, 33-40.	1.3	13
25	AB1020â€Evaluation of the Disease Course of Italian Children with Juvenile Idiopathic Arthritis Treated with Etanercept: Preliminary Results in 1019 Patients. Annals of the Rheumatic Diseases, 2015, 74, 1239.3-1240.	0.5	0
26	OP0270â€Further Validation of the Hybrid MMT/CMAS (HMC), A New Measure of Muscle Disease Activity in Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2015, 74, 174.2-174.	0.5	0
27	OP0150â€Development and Preliminary Validation of a New Composite Disease Activity Measure for Juvenile Dermatomyositis. Annals of the Rheumatic Diseases, 2015, 74, 125.1-125.	0.5	0
28	A controlled trial of intra-articular corticosteroids with or without methotrexate in oligoarticular juvenile idiopathic arthritis. Pediatric Rheumatology, 2014, 12, .	0.9	0
29	Evaluation of the disease course of Italian children with juvenile idiopathic arthritis treated with etanercept: preliminary results in 772 patients. Pediatric Rheumatology, 2014, 12, P130.	0.9	0
30	PReS-FINAL-2011: Preliminary validation of a new hybrid measure of muscle strength for juvenile dermatomyositis. Pediatric Rheumatology, 2013, $11$ , .	0.9	1
31	PReS-FINAL-2012: Introducing a new approach to clinical care of juvenile dermatomyositis: the juvenile dermatomyositis multidimensional assessment report. Pediatric Rheumatology, 2013, 11, .	0.9	4
32	PReS-FINAL-2143: Treat-to-target strategy in juvenile idiopathic arthritis: experience in $175$ newly-diagnosed patients. Pediatric Rheumatology, 2013, $11$ , .	0.9	0
33	PReS-FINAL-2193: Assessment of construct validity of new measures of global disease activity, physical function and quality of life in children with juvenile dermatomyositis. Pediatric Rheumatology, 2013, 11, .	0.9	0
34	FRI0336â€Comparison of construct validity of two functional ability measures in children with juvenile dermatomyositis:. Annals of the Rheumatic Diseases, 2013, 71, 427.3-428.	0.5	1
35	Development and initial validation of a new functional ability tool for juvenile dermatomyositis. Pediatric Rheumatology, 2011, 9, .	0.9	0
36	A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report. Journal of Rheumatology, 2011, 38, 938-953.	1.0	159

## ADELE CIVINO

#	Article	IF	CITATIONS
37	The Quality of Life of Children and Adolescents with X-Linked Agammaglobulinemia. Journal of Clinical Immunology, 2009, 29, 501-507.	2.0	34
38	Anaplastic large cell lymphoma (Ki-1+/CD30+) in childhood. Medical and Pediatric Oncology, 1993, 21, 402-410.	1.0	54